Major Depressive Disorder Epidemiology Forecast 2025-2034

Major depressive disorder or clinical depression is one of the most common mental health conditions, affecting 5% to 17% of individuals at some point in their lives. Studies show that at least 21 million people in the United States experience a major depressive episode.

Major Depressive Disorder Epidemiology Forecast Report Coverage

Expert Market Research's “Major Depressive Disorder Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of major depressive disorder. It projects the future incidence and prevalence rates of major depressive disorder across various populations. The study covers age and type as major determinants of the major depressive disorder-affected population. The report highlights patterns in the prevalence of major depressive disorder over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of major depressive disorder in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Major Depressive Disorder: Disease Overview

Major depressive disorder (MDD), also known as clinical depression, causes a persistently low mood, a loss of interest or pleasure in activities, and other symptoms for a period of at least two weeks. This mental health condition may occur due to psychological, biological, and social sources of distress. A major depressive episode can also be associated with suicidal thoughts. Clinical depression can affect people of all ages but most cases are observed in people in their 20s.

Major Depressive Disorder: Treatment Overview

Major depressive disorder is usually treated with a combination of medication, psychotherapy, or other treatments. Psychotherapy includes cognitive behavioral therapy, interpersonal psychotherapy, or problem-solving therapy. Antidepressants are commonly prescribed to patients but can take 4 to 8 weeks to show their effectiveness. In cases of severe depression where the patient fails to respond to other treatments, electroconvulsive therapy may be used to restore the brain's chemical balance.

Epidemiology

The major depressive disorder epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for major depressive disorder by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for major depressive disorder and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Approximately 5% to 17% of people are affected by major depressive disorder or clinical depression at some point in their lives. It is reported that 5% to 10% of clinical depression patients develop bipolar disorder.
• As per the World Health Organisation, around 3.8% of the global population, or 280 million people worldwide experience depression, including 5% of adults (4% of men and 6% of women) and 5.7% of people over 60 years.
• About 9.5% of American adults (aged 18 and above) are projected to experience a depressive illness, including major depressive disorder, dysthymia, and bipolar disorder, every year.
• Studies indicate that episodes of major depression are more common among females (10.3%) as compared to males (6.2%). Major depressive disorder is also reported to be more prevalent in people aged between 18 and 25 years (18.6%).

Country-wise Major Depressive Disorder Epidemiology

The major depressive disorder epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of major depressive disorder varies significantly between countries owing to the differences in factors such as genetic predisposition, environmental stressors, availability and quality of mental health services, and societal attitudes toward mental health, among others. It is estimated that at least 21 million individuals in the United States experience a major depressive episode in 2021, representing 8.3% of the adult population in the country.

Country Specific Stats:

Country

Prevalence (Unit)

United States

United Kingdom

Germany

Italy

France

Spain

Japan

India

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of major depressive disorder based on several factors.
• Major Depressive Disorder Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of major depressive disorder are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of major depressive disorder epidemiology in the 8 major markets?
• What will be the total number of patients with major depressive disorder across the 8 major markets during the forecast period?
• What was the country-wise prevalence of major depressive disorder in the 8 major markets in the historical period?
• Which country will have the highest number of major depressive disorder patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of major depressive disorder during the forecast period of 2025-2034?
• What are the currently available treatments for major depressive disorder?
• What are the disease risks, signs, symptoms, and unmet needs of major depressive disorder?

Related Reports

Anxiety and Depression Treatment Market

Treatment Resistant Depression Market

Major Depressive Disorder Market